Engineered CAF-cancer Cell Hybrid Membrane Biomimetic Dual-targeted Integrated Platform for Multi-dimensional Treatment of Ovarian Cancer

Overview

Journal J Nanobiotechnology

Publisher Biomed Central

Date 2025 Feb 5

PMID 39910555

Authors

Yuwei Yao

Jiarui Zhang

Kexin Huang

Yingying Peng

Shuangshuang Cheng

Shuangge Liu

Ting Zhou

Jinhua Chen

Haojia Li

Yingchao Zhao

Hongbo Wang

Affiliations

Soon will be listed here.

Abstract

Background: The efficacy of current therapies for ovarian cancer is limited due to the multilevel and complex tumor microenvironment (TME), which induces drug resistance and tumor progression in a single treatment regimen. Additionally, poor targeting and insufficient tissue penetration are important constraints in ovarian cancer treatment.

Result: We constructed PH20-overexpressing cancer-associated fibroblast (CAF)-cancer hybrid-cell membrane vesicles (PH20/CCM) for the dual-targeted delivery of carboplatin (CBP) and siRNA targeting p65 (sip65) loaded on the poly (dimethyl diallyl ammonium chloride) (PDDA)-modified MXene (PMXene), named PMXene@CBP-sip65 (PMCS). The nanoparticle PH20/CCM@PMCS could penetrate the extracellular matrix of tumor tissues and target both cancer cells and CAFs. After tumor cell internalization, these nanoparticles significantly inhibited cancer cell proliferation, generated reactive oxygen species, induced endoplasmic reticulum stress, and triggered immunogenic cell death. After CAF internalization, they inhibited pro-tumor factor release and activated immune effects, promoting immune system infiltration. In an experiment with ID8 homograft-carrying mice, PH20/CCM@PMCS significantly improved tumor inhibition and enhanced immune infiltration in tumor tissues.

Conclusion: These new therapeutic nanoparticles can simultaneously target tumor cells, CAFs, immune cells, and the extracellular matrix, thereby increasing treatment sensitivity and improving the TME. Therefore, these TME-regulating nanoparticles, combining specificity, efficiency, and effectiveness, provide new insights into ovarian cancer treatment.

References

Gong C, Yu X, You B, Wu Y, Wang R, Han L . Macrophage-cancer hybrid membrane-coated nanoparticles for targeting lung metastasis in breast cancer therapy. J Nanobiotechnology. 2020; 18(1):92. PMC: 7298843. DOI: 10.1186/s12951-020-00649-8. View

Huang T, Tan X, Huang H, Li Y, Liu B, Liu K . Targeting cancer-associated fibroblast-secreted WNT2 restores dendritic cell-mediated antitumour immunity. Gut. 2021; 71(2):333-344. PMC: 8762012. DOI: 10.1136/gutjnl-2020-322924. View

Chowdhury P, Bhusetty Nagesh P, Hollingsworth T, Jaggi M, Chauhan S, Yallapu M . Coating a Self-Assembly Nanoconstruct with a Neutrophil Cell Membrane Enables High Specificity for Triple Negative Breast Cancer Treatment. ACS Appl Bio Mater. 2022; . DOI: 10.1021/acsabm.2c00614. View

Paget S . The distribution of secondary growths in cancer of the breast. 1889. Cancer Metastasis Rev. 1989; 8(2):98-101. View

Zhang H, Hao C, Wang Y, Ji S, Zhang X, Zhang W . Sohlh2 inhibits human ovarian cancer cell invasion and metastasis by transcriptional inactivation of MMP9. Mol Carcinog. 2015; 55(7):1127-37. DOI: 10.1002/mc.22355. View

Planells-Cases R, Lutter D, Guyader C, Gerhards N, Ullrich F, Elger D . Subunit composition of VRAC channels determines substrate specificity and cellular resistance to Pt-based anti-cancer drugs. EMBO J. 2015; 34(24):2993-3008. PMC: 4687416. DOI: 10.15252/embj.201592409. View

Yang L, Li H, Jiang Y, Zuo J, Liu W . Inhibition of mortalin expression reverses cisplatin resistance and attenuates growth of ovarian cancer cells. Cancer Lett. 2013; 336(1):213-21. DOI: 10.1016/j.canlet.2013.05.004. View

Orimo A, Gupta P, Sgroi D, Arenzana-Seisdedos F, Delaunay T, Naeem R . Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell. 2005; 121(3):335-48. DOI: 10.1016/j.cell.2005.02.034. View

Xiong J, Wu M, Chen J, Liu Y, Chen Y, Fan G . Cancer-Erythrocyte Hybrid Membrane-Camouflaged Magnetic Nanoparticles with Enhanced Photothermal-Immunotherapy for Ovarian Cancer. ACS Nano. 2021; 15(12):19756-19770. DOI: 10.1021/acsnano.1c07180. View

10.

Xu Y, Ma J, Zheng Q, Wang Y, Hu M, Ma F . MPSSS impairs the immunosuppressive function of cancer-associated fibroblasts via the TLR4-NF-κB pathway. Biosci Rep. 2019; 39(5). PMC: 6509060. DOI: 10.1042/BSR20182171. View

11.

Jayson G, Kohn E, Kitchener H, Ledermann J . Ovarian cancer. Lancet. 2014; 384(9951):1376-88. DOI: 10.1016/S0140-6736(13)62146-7. View

12.

Zeng H, Hou Y, Zhou X, Lang L, Luo H, Sun Y . Cancer-associated fibroblasts facilitate premetastatic niche formation through lncRNA SNHG5-mediated angiogenesis and vascular permeability in breast cancer. Theranostics. 2022; 12(17):7351-7370. PMC: 9691361. DOI: 10.7150/thno.74753. View

13.

Morgan M, Liu Z . Crosstalk of reactive oxygen species and NF-κB signaling. Cell Res. 2010; 21(1):103-15. PMC: 3193400. DOI: 10.1038/cr.2010.178. View

14.

Li C, Guo H, Zhai P, Yan M, Liu C, Wang X . Spatial and Single-Cell Transcriptomics Reveal a Cancer-Associated Fibroblast Subset in HNSCC That Restricts Infiltration and Antitumor Activity of CD8+ T Cells. Cancer Res. 2023; 84(2):258-275. PMC: 10790129. DOI: 10.1158/0008-5472.CAN-23-1448. View

15.

Polcher M, Rudlowski C, Friedrichs N, Mielich M, Holler T, Wolfgarten M . In vivo intratumor angiogenic treatment effects during taxane-based neoadjuvant chemotherapy of ovarian cancer. BMC Cancer. 2010; 10:137. PMC: 2873383. DOI: 10.1186/1471-2407-10-137. View

16.

Khalaf K, Hana D, Chou J, Singh C, Mackiewicz A, Kaczmarek M . Aspects of the Tumor Microenvironment Involved in Immune Resistance and Drug Resistance. Front Immunol. 2021; 12:656364. PMC: 8190405. DOI: 10.3389/fimmu.2021.656364. View

17.

Farrera-Sal M, Moreno R, Mato-Berciano A, Maliandi M, Bazan-Peregrino M, Alemany R . Hyaluronidase expression within tumors increases virotherapy efficacy and T cell accumulation. Mol Ther Oncolytics. 2021; 22:27-35. PMC: 8321894. DOI: 10.1016/j.omto.2021.05.009. View

18.

Li Z, Sun C, Qin Z . Metabolic reprogramming of cancer-associated fibroblasts and its effect on cancer cell reprogramming. Theranostics. 2021; 11(17):8322-8336. PMC: 8343997. DOI: 10.7150/thno.62378. View

19.

Shen L, Li M, Wei W, Guan X, Liu J . Neuroprotective Effects of Macrophage Membrane-Derived Curcumin-Loaded Carriers against 1-Methyl-4-phenylpyridinium-Induced Neuronal Damage. ACS Omega. 2021; 6(47):32133-32141. PMC: 8637945. DOI: 10.1021/acsomega.1c04894. View

20.

Shen W, Jia C, Liao L, Chen L, Hou C, Liu Y . Copper(II) Complexes of Halogenated Quinoline Schiff Base Derivatives Enabled Cancer Therapy through Glutathione-Assisted Chemodynamic Therapy and Inhibition of Autophagy Flux. J Med Chem. 2022; 65(6):5134-5148. DOI: 10.1021/acs.jmedchem.2c00133. View